Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: Non-Hodgkin's Lymphoma

In brief

This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.

Key facts

Study ID

NCT00285428

Run by

Gilead Sciences

People needed

82

Starts

2004-09-01

Expected to finish

2007-10-01

Last updated by the study team

2021-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease

Where it is running

• New York Presbyterian Hospital/Cornell Medical Center — New York, New York, United States
• University Hospital of Pennsylvania — Philadelphia, Pennsylvania, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.